SG178476A1 - Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes - Google Patents

Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes Download PDF

Info

Publication number
SG178476A1
SG178476A1 SG2012011144A SG2012011144A SG178476A1 SG 178476 A1 SG178476 A1 SG 178476A1 SG 2012011144 A SG2012011144 A SG 2012011144A SG 2012011144 A SG2012011144 A SG 2012011144A SG 178476 A1 SG178476 A1 SG 178476A1
Authority
SG
Singapore
Prior art keywords
adenovirus
seq
modified
hvr1
sequence
Prior art date
Application number
SG2012011144A
Other languages
English (en)
Inventor
Takayuki Shiratsuchi
Moriya Tsuji
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of SG178476A1 publication Critical patent/SG178476A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2012011144A 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes SG178476A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2009/054212 WO2011022002A1 (en) 2009-08-18 2009-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
PCT/US2010/045952 WO2011022522A1 (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Publications (1)

Publication Number Publication Date
SG178476A1 true SG178476A1 (en) 2012-03-29

Family

ID=43607237

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012011144A SG178476A1 (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
SG10201404970PA SG10201404970PA (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201404970PA SG10201404970PA (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Country Status (16)

Country Link
US (1) US20170348405A1 (https=)
EP (2) EP3412306A3 (https=)
JP (2) JP5947719B2 (https=)
KR (1) KR20120094469A (https=)
CN (2) CN105770880A (https=)
BR (1) BR112012003808A2 (https=)
CA (1) CA2769415A1 (https=)
IL (1) IL217709A (https=)
MX (1) MX339830B (https=)
NZ (1) NZ598703A (https=)
PH (1) PH12012500164A1 (https=)
RU (1) RU2585228C2 (https=)
SG (2) SG178476A1 (https=)
UA (1) UA108081C2 (https=)
WO (2) WO2011022002A1 (https=)
ZA (1) ZA201201286B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2014196648A1 (en) * 2013-06-03 2014-12-11 Vlp Therapeutics, Llc Malaria vaccine
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017048689A1 (en) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US10517938B2 (en) 2016-01-21 2019-12-31 Janssen Vaccines & Prevention B.V. Adenovirus based malaria vaccine encoding and displaying a malaria antigen
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN107841513B (zh) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 基于M2e表位的广谱型流感疫苗
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN108192876A (zh) * 2017-12-07 2018-06-22 东莞市第八人民医院 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
JP2021178021A (ja) * 2020-05-14 2021-11-18 株式会社三洋物産 遊技機
WO2022234276A1 (en) * 2021-05-04 2022-11-10 SpyBiotech Limited Adenoviral vectors and vaccines thereof
EP4404947A4 (en) * 2021-09-23 2025-12-10 Sagittarius Bio Inc Adenovirus and Methods of Using Adenovirus
CN120944926B (zh) * 2025-10-15 2026-01-30 华中科技大学同济医学院附属同济医院 衣壳表面展示超大片段抗原的重组腺病毒、构建方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066623A (en) * 1993-11-23 2000-05-23 The United States Of America As Represented By The Secretary Of The Navy Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
CA2502268A1 (en) * 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
US7611868B2 (en) * 2003-05-14 2009-11-03 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Recombinant modified adenovirus fiber protein
JP2005287309A (ja) * 2004-03-31 2005-10-20 Dnavec Research Inc 遺伝子導入を増強するための薬剤および方法
JP4843613B2 (ja) * 2004-10-13 2011-12-21 クルセル ホランド ベー ヴェー 改良されたアデノウイルスベクターおよびその使用方法
AU2006284756B2 (en) * 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2008140474A1 (en) * 2006-10-26 2008-11-20 Johns Hopkins University Recombinant adenovirus vaccines

Also Published As

Publication number Publication date
RU2012110255A (ru) 2013-09-27
JP5947719B2 (ja) 2016-07-06
JP6293181B2 (ja) 2018-03-14
MX2012002131A (es) 2012-04-11
EP3412306A2 (en) 2018-12-12
MX339830B (es) 2016-06-13
KR20120094469A (ko) 2012-08-24
ZA201201286B (en) 2013-05-29
CN103025349A (zh) 2013-04-03
CN103025349B (zh) 2016-05-18
EP3412306A3 (en) 2019-01-02
BR112012003808A2 (pt) 2016-11-16
UA108081C2 (uk) 2015-03-25
JP2016146837A (ja) 2016-08-18
IL217709A (en) 2016-05-31
WO2011022002A1 (en) 2011-02-24
US20170348405A1 (en) 2017-12-07
WO2011022522A1 (en) 2011-02-24
HK1179508A1 (zh) 2013-10-04
EP2467157A1 (en) 2012-06-27
CN105770880A (zh) 2016-07-20
CA2769415A1 (en) 2011-02-24
SG10201404970PA (en) 2014-10-30
JP2013502221A (ja) 2013-01-24
IL217709A0 (en) 2012-03-29
RU2585228C2 (ru) 2016-05-27
EP2467157A4 (en) 2014-01-22
AU2010286187A1 (en) 2012-02-16
NZ598703A (en) 2014-04-30
PH12012500164A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
JP6293181B2 (ja) 免疫原性マラリア原虫周辺スポロゾイトタンパク質エピトープによる組換えアデノウイルスの改変
JP2013502221A5 (https=)
US9555089B2 (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
WO2012023995A1 (en) Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
US7741099B2 (en) Adenoviral vectors and uses thereof
JP5882741B2 (ja) サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
EP2998316B1 (en) Novel method and compositions
ES2871907T3 (es) Portadores de vacuna de adenovirus de chimpancé
EP2160197B1 (en) Adenoviral vector encoding malaria antigen
JP5222289B2 (ja) マラリア用ワクチン
US20140294890A1 (en) Recombinant Adenovirus Vaccines
HU228327B1 (en) Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
IL299592A (en) Nucleotide and Amino Acid Sequences of Gorilla Adenovirus Vectors Containing Them and Their Uses
EP3368068B1 (en) Virus like particle with efficient epitope display
Shiratsuchi et al. A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII
Bruder et al. Molecular vaccines for malaria
Palma et al. Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice
AU2010286187B2 (en) Modification of recombinant adenovirus with immunogenic Plasmodium circumsporozoite protein epitopes
HK1179508B (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
JP2018078894A (ja) サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
ES2377964T3 (es) Vacunas contra la malaria basadas en virus recombinante